Search

Author/Creator Steinhart, C.

1. Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Issue 1 (January 2019)

Authors:
Aboud, M.; Kaplan, R.; Lombaard, J.; Zhang, F.; Hidalgo, J.; Mamedova, E.; Losso, M.; Chetchotisakd, P.; Brites, C.; Sievers, J.; Brown, D.; Hopking, J.; Underwood, M.; Nascimento, M.; Gartland, M.; Smith, K.; Steinhart, C.; Gatell, J.
Journal:
Journal of infection and public health
Issue:
Volume 12:Issue 1(2019)
Page Start:
107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019)

Authors:
Orkin, C.; Porteiro, N.; Berhe, M.; Dretler, R.; Viciana, P.; Tseng, Y.; Oprea, C.; Johnson, M.; Kulagin, V.; Man, C.; Sievers, J.; Currie, A.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Aboud, M.; Smith, K.; Gartland, M.; Steinhart, C.
Journal:
Journal of infection and public health
Issue:
Volume 12:Issue 1(2019)
Page Start:
147
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search